Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503)

医学 围手术期 肺癌 外科 析因分析 内科学 临床终点 癌症 随机对照试验
作者
Nasser K. Altorki,Xiaofei Wang,Dennis A. Wigle,Lin Gu,Gail Darling,Ahmad S. Ashrafi,Rodney Landrenau,Daniel Miller,Moïshe Liberman,David R. Jones,Robert J. Keenan,Massimo Conti,Gavin Wright,Linda J. Veit,Suresh S. Ramalingam,Mohamed Kamel,Harvey I. Pass,John D. Mitchell,Thomas E. Stinchcombe,Everett E. Vokes,Leslie J. Kohman
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:6 (12): 915-924 被引量:291
标识
DOI:10.1016/s2213-2600(18)30411-9
摘要

Background Increased detection of small-sized, peripheral, non-small-cell lung cancer has renewed interest in sublobar resection instead of lobectomy, the traditional standard of care for early-stage lung cancer. We aimed to assess morbidity and mortality associated with lobar and sublobar resection for early-stage lung cancer. Methods CALGB/Alliance 140503 is a multicentre, international, non-inferiority, phase 3 trial in patients with peripheral non-small-cell lung cancer clinically staged as T1aN0. Patients were recruited from 69 academic and community-based institutions in Australia, Canada, and the USA. Patients were randomly assigned intraoperatively to either lobar or sublobar resection. The random assignment was based on permuted block randomisation without concealment and was stratified according to radiographic tumour size, histology, and smoking status. The primary endpoint of the trial is disease-free survival; here, we report a post-hoc, exploratory, comparative analysis of perioperative mortality and morbidity associated with lobar and sublobar resection. Perioperative mortality was defined as death from any cause within 30 days and 90 days of surgical intervention and was calculated for all randomised patients. Morbidity was graded using Common Terminology Criteria for Adverse Events version 4.0. All analyses were done on an intention-to-treat basis for randomised patients with data available. This trial is registered with ClinicalTrials.gov, number NCT00499330. Findings Between June 15, 2007, and March 13, 2017, 697 patients were randomly allocated to either lobar resection (n=357) or sublobar resection (n=340; 59% wedge resection). Six (0·9%) patients died by 30 days, four (1·1%) after lobar resection and two (0·6%) after sublobar resection; by 90 days, ten (1·4%) patients had died, six (1·7%) after lobar resection and four (1·2%) after sublobar resection (difference at 30 days, 0·5%, 95% CI −1·1 to 2·3; difference at 90 days, 0·5%, 95% CI −1·5 to 2·6). An adverse event of any grade occurred in 193 (54%) of 355 patients after lobar resection and 172 (51%) of 337 patients after sublobar resection. Adverse events of grade 3 or worse occurred in 54 (15%) patients assigned lobar resection and in 48 (14%) patients assigned sublobar resection. No differences between surgical approaches were noted in cardiac or pulmonary complications. Grade 3 haemorrhage (requiring transfusion) occurred in six (2%) patients assigned lobar resection and eight (2%) patients assigned sublobar resection. Prolonged air leak occurred in nine (3%) patients after lobar resection and two (1%) patients after sublobar resection. Interpretation Our post-hoc analysis showed that perioperative mortality and morbidity did not seem to differ between lobar and sublobar resection in physically and functionally fit patients with clinical T1aN0 non-small-cell lung cancer. These data may affect the daily choices made by patients and their doctors in establishing the best treatment approach for stage I lung cancer. Funding National Cancer Institute.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
小马甲应助Lam采纳,获得10
刚刚
JJXIONG完成签到,获得积分10
1秒前
河马发布了新的文献求助10
2秒前
2秒前
可爱的函函应助肖肖采纳,获得10
3秒前
CodeCraft应助平常的紫蓝采纳,获得10
3秒前
好宝宝完成签到,获得积分10
3秒前
3237924531发布了新的文献求助10
4秒前
hdy331完成签到,获得积分10
4秒前
完美世界应助123采纳,获得10
5秒前
5秒前
怕孤独的忆南完成签到,获得积分10
7秒前
追风完成签到 ,获得积分10
8秒前
8秒前
yao完成签到,获得积分10
8秒前
常芹发布了新的文献求助10
9秒前
ED应助科研路漫漫采纳,获得10
9秒前
10秒前
布鲁克完成签到,获得积分10
11秒前
11秒前
量子星尘发布了新的文献求助10
12秒前
今后应助朴实的绣连采纳,获得30
12秒前
<小天才>发布了新的文献求助10
14秒前
14秒前
15秒前
Smy完成签到 ,获得积分10
15秒前
在水一方应助梁晓雯采纳,获得10
16秒前
Yy123发布了新的文献求助10
16秒前
tao发布了新的文献求助10
16秒前
3237924531完成签到,获得积分10
16秒前
健忘小霜完成签到,获得积分10
17秒前
18秒前
scholar完成签到,获得积分10
19秒前
wei发布了新的文献求助10
19秒前
鳗鱼灵阳完成签到,获得积分20
20秒前
20秒前
21秒前
无情的聋五完成签到 ,获得积分10
21秒前
Owen应助QQiang6采纳,获得10
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988838
求助须知:如何正确求助?哪些是违规求助? 3531250
关于积分的说明 11252914
捐赠科研通 3269838
什么是DOI,文献DOI怎么找? 1804820
邀请新用户注册赠送积分活动 881943
科研通“疑难数据库(出版商)”最低求助积分说明 809028